PLYMOUTH CONFERENCE, Pa. and also SEOUL, South Korea, June 20, 2016 (GLOBE NEWSWIRE)– Inovio Pharmaceuticals, Inc. (NASDAQ: INO) and GeneOne Life Science, Inc. (KSE:011000) today revealed that they have actually gotten approval to start a phase I human test to evaluate Inovio’s Zika DNA vaccination (GLS-5700) to prevent infection from this concerning virus. Zika virus vaccine will tested soon.
In preclinical screening this artificial injection induced robust antibody and also T cell feedbacks in little as well as huge animal models, showing the item’s possibility to avoid infection from this harmful virus in human beings.
This stage I, open-label, dose-ranging research study with 40 healthy subjects will assess the safety, tolerability and immunogenicity of GLS-5700 administered intradermally with CELLECTRA ®, Inovio’s proprietary DNA shipment gadget.
Dr. J. Joseph Kim, Inovio’s President & CEO, said, “We are proud to have attained the approval to initiate the first Zika vaccine study in human volunteers. As of May 2016, 58 countries and territories reported continuing mosquito-borne transmission of the Zika virus; the incidences of viral infection and medical conditions caused by the virus are expanding, not contracting. We plan to dose our first subjects in the next weeks and expect to report phase I interim results later this year.”
Mr. Young K. Park, GeneOne Life Science’s President & Chief Executive Officer, claimed, “It is an honor for our company to help usher this Zika vaccine through the clinical and regulatory process. We look forward to conducting this trial with the goal of achieving products to combat this dreaded virus.”
Inovio and GeneOne are establishing the Zika vaccine, GLS-5700, with academic partners from the United States and Canada with whom they have actually formerly worked together to progress Inovio’s Ebola as well as MERS injections right into scientific development.
About the Zika Virus
Initially identified in Uganda, Zika infection subsequently infected equatorial Asia and over the past 2 years possesses rapidly spread with the South Pacific, including Hawaii, and to South The U.S.A., Central America, as well as the Caribbean. Zika infection is a flavivirus, a family of infections including yellow high temperature, dengue, as well as West Nile infection, which are presented to individuals through mosquito bites.
Since the Aedes types of mosquitoes that spreads out Zika infection is discovered throughout the globe there is worry that Zika will certainly remain to infect brand-new nations and also areas. Zika can also be sexually sent.
The most typical signs of Zika infection are high temperature, rash, joint pain, and also conjunctivitis. A lot more seriously, Zika must been connected to an extreme abnormality called microcephaly which arises from infection while pregnant. Microcephaly is an unusual problem marked by an extraordinarily tiny head and also insufficient brain advancement.
Zika is also associated with Guillain-Barré syndrome, which causes muscle weakness of the arm or legs and in severe situations may create virtually total paralysis consisting of the lack of ability to breath. Recent reports recommend Zika may likewise be linked to various other neurological irregularities.
No injection or therapy currently exists for the Zika virus. But now zika virus vaccine give our hope.
About GeneOne Life Science
GeneOne Life Science, Inc. is a worldwide DNA injection designer as well as leading agreement producer of DNA plasmid-based representatives for preclinical as well as medical tests for worldwide firms and also organizations. It looks into and crafts DNA injections to prevent and also deal with incurable illness in South Korea and worldwide. The firm is locateded in Seoul, South Korea. VGXI, Inc., GeneOne’s wholly-owned manufacturing subsidiary located in Texas, is the biggest pure-play cGMP DNA plasmid manufacturing center in the world. VGXI made the Zika vaccination as well as various other emerging condition vaccines consisting of Ebola and also MERS.
Regarding Inovio Pharmaceuticals, Inc
Inovio is taking immunotherapy to the following degree in the fight against cancer cells as well as infectious diseases. We are the only immunotherapy company that possesses reported producing T cells in vivo in high quantity that are fully practical and also whose killing ability associates with appropriate scientific results with a desirable security account. With an expanding profile of immune treatments, the company is progressing an expanding preclinical and also medical stage item pipe.
Partners and partners include MedImmune, Roche, The Wistar Institute, University of Pennsylvania, DARPA, GeneOne Life Science, Plumbline Life Sciences, Drexel University, NIH, HIV Vaccines Test Network, National Cancer Institute, UNITED STATE Military HIV Research study Program, as well as College of Manitoba.